342 related articles for article (PubMed ID: 28692110)
1. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.
Leenaerts D; Aernouts J; Van Der Veken P; Sim Y; Lambeir AM; Hendriks D
Thromb Haemost; 2017 Jul; 117(8):1498-1508. PubMed ID: 28692110
[TBL] [Abstract][Full Text] [Related]
2. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma.
Leurs J; Wissing BM; Nerme V; Schatteman K; Björquist P; Hendriks D
Thromb Haemost; 2003 Feb; 89(2):264-71. PubMed ID: 12574805
[TBL] [Abstract][Full Text] [Related]
3. Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
Claesen K; Mertens JC; Leenaerts D; Hendriks D
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477318
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the procarboxypeptidase U (proCPU, TAFI, proCPB2) system due to hemolysis.
Mertens JC; Claesen K; Leenaerts D; Sim Y; Lambeir AM; Hendriks D
J Thromb Haemost; 2019 Jun; 17(6):878-884. PubMed ID: 30887647
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.
Leenaerts D; Bosmans JM; van der Veken P; Sim Y; Lambeir AM; Hendriks D
J Thromb Haemost; 2015 Dec; 13(12):2227-32. PubMed ID: 26340515
[TBL] [Abstract][Full Text] [Related]
6. Carboxypeptidase U (CPU, carboxypeptidase B2, activated thrombin-activatable fibrinolysis inhibitor) inhibition stimulates the fibrinolytic rate in different in vitro models.
Leenaerts D; Loyau S; Mertens JC; Boisseau W; Michel JB; Lambeir AM; Jandrot-Perrus M; Hendriks D
J Thromb Haemost; 2018 Oct; 16(10):2057-2069. PubMed ID: 30053349
[TBL] [Abstract][Full Text] [Related]
7. Proteolytic activation of purified human procarboxypeptidase U.
Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
Clin Chim Acta; 2000 Feb; 292(1-2):25-40. PubMed ID: 10686274
[TBL] [Abstract][Full Text] [Related]
8. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
9. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation.
Mosnier LO; von dem Borne PA; Meijers JC; Bouma BN
Thromb Haemost; 1998 Nov; 80(5):829-35. PubMed ID: 9843179
[TBL] [Abstract][Full Text] [Related]
10. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism.
Leurs J; Nerme V; Sim Y; Hendriks D
J Thromb Haemost; 2004 Mar; 2(3):416-23. PubMed ID: 15009457
[TBL] [Abstract][Full Text] [Related]
11. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis.
Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
Thromb Haemost; 1999 Dec; 82(6):1718-21. PubMed ID: 10613660
[TBL] [Abstract][Full Text] [Related]
12. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
[TBL] [Abstract][Full Text] [Related]
13. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma.
Broze GJ; Higuchi DA
Blood; 1996 Nov; 88(10):3815-23. PubMed ID: 8916945
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-activatable fibrinolysis inhibitor.
Marx PF
Curr Med Chem; 2004 Sep; 11(17):2335-48. PubMed ID: 15379716
[TBL] [Abstract][Full Text] [Related]
15. Effect of Statin Therapy on the Carboxypeptidase U (CPU, TAFIa, CPB2) System in Patients With Hyperlipidemia: A Proof-of-concept Observational Study.
Claesen K; Mertens JC; Basir S; De Belder S; Maes J; Bosmans J; Stoffelen H; De Meester I; Hendriks D
Clin Ther; 2021 May; 43(5):908-916. PubMed ID: 33910760
[TBL] [Abstract][Full Text] [Related]
16. Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.
Garabon JJW; Boffa MB
J Thromb Thrombolysis; 2023 Aug; 56(2):283-290. PubMed ID: 37310666
[TBL] [Abstract][Full Text] [Related]
17. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma.
Schatteman KA; Goossens FJ; Scharpé SS; Neels HM; Hendriks DF
Clin Chem; 1999 Jun; 45(6 Pt 1):807-13. PubMed ID: 10351989
[TBL] [Abstract][Full Text] [Related]
18. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
19. An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis.
Heylen E; Willemse J; Hendriks D
Front Biosci (Landmark Ed); 2011 Jun; 16(7):2427-50. PubMed ID: 21622187
[TBL] [Abstract][Full Text] [Related]
20. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
